We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Tysabri Submission Includes Label Revisions, Risk Management Plan
Tysabri Submission Includes Label Revisions, Risk Management Plan
September 30, 2005
Biogen Idec and Elan’s plan to revive its withdrawn multiple sclerosis (MS) drug Tysabri includes revisions to the product’s label, as well as the establishment of a risk management plan for the drug.